TASLY(SH:600535) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-02 23:40Core Viewpoint - Tian Shi Li Pharmaceutical Group Co., Ltd. has announced its "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, aiming to enhance company quality and investor value while ensuring compliance with regulatory requirements [11][23]. Group 1: Board Meeting Resolutions - The 13th meeting of the 9th Board of Directors was held on September 2, 2025, with 14 out of 15 directors present, and all resolutions were passed unanimously [1][2]. - Resolutions included the approval of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan, the implementation of the Board's authority, and the establishment of the "Board Authorization Management System" [1][3][4]. Group 2: Shareholder Meeting Outcomes - The fourth extraordinary general meeting of shareholders took place on September 2, 2025, with all resolutions passed without opposition [6][7]. - The meeting adopted the 2025 semi-annual profit distribution plan, which was approved by a majority of the voting shareholders [8][10]. Group 3: Financial Performance - In the first half of 2025, the company reported total revenue of 4.288 billion yuan, with pharmaceutical industrial revenue at 3.879 billion yuan, maintaining stability compared to the previous year [12]. - The net profit attributable to shareholders reached 775 million yuan, reflecting a year-on-year increase of 16.97%, while the debt-to-asset ratio decreased from 19.13% to 18.43% [12]. Group 4: Strategic Focus and Innovation - The company aims to enhance its operational quality by focusing on core business areas and leveraging innovation to become a leader in the Chinese pharmaceutical market [11][12]. - The action plan emphasizes the development of integrated solutions for cardiovascular, neurological, and digestive diseases, optimizing product research and development [13][14]. Group 5: Governance and Compliance - The company is committed to improving its governance structure and ensuring compliance with relevant laws and regulations, enhancing decision-making processes and internal controls [17][18]. - Future efforts will focus on strengthening the board's effectiveness and protecting the rights of minority shareholders [18][21]. Group 6: Investor Relations and Returns - The company prioritizes investor relations, aiming to enhance communication and transparency while ensuring reasonable returns for shareholders [22][19]. - A cash dividend of 2.1 yuan per share is proposed for the 2025 semi-annual profit distribution, representing 40.50% of the net profit for that period [20].